Navigation Links
Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
Date:3/4/2010

Dr. David Bar-Or, Ampio Pharmaceuticals' founder and Chief Scientific Officer, stated, "I have been working for over 30 years on finding solutions to important diseases that can impact an aging population. My role as the Director of Trauma Research at two major Colorado Level One Trauma Centers has given me the unique opportunity to study a variety of diseases in both clinical and research settings."

Ampio Pharmaceuticals discovers and develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease.  The company develops Repurposed Drugs because they have strong potential to be safe and effective while their shorter development times can significantly increase near-term value.  The product pipeline includes new uses for previously approved drugs, some of which are now starting clinical trials, and new molecular entities ("NMEs"). A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize the company's product development programs.  By concentrating on development of Repurposed Drugs, approval timelines, costs and risk of clinical failure are reduced due to the fact that the Repurposed Drug has previously been found to be safe and effective, generally at higher dosage rates, in distinct therapeutic categories."

Safe Harbor Statement


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014  Amgen (NASDAQ: ... Sanders Williams , M.D., president of Gladstone Institutes and ... "We are pleased to welcome Dr. ... Robert A. Bradway , chairman and chief executive ... in academic medicine and his direct experience in our ...
(Date:10/17/2014)... October 17, 2014 ... Market by Technique (Optical Coherence Tomography, Hyperspectral ... Application (Ophthalmology, Neurology, Oncology, Cardiology) - Global ... studies the Optical Imaging market over the ... valued at $917.1 million in 2014 and ...
(Date:10/17/2014)... Md. , Oct. 17, 2014 ... for Medical Technology Policy: The Green ... the FDA, public and private payers, medical device ... clinicians, and other experts January 12, 2015 at ... and value of weight loss treatments.  Participants will ...
Breaking Medicine Technology:Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
(Date:10/20/2014)... Ga. (PRWEB) October 20, 2014 ... and relationship-marketing firm, announced today that William H. ... named the 2014 ISE® Luminary Leadership Award winner. ... the achievements of an outstanding leader and industry ... and contributions in advancing the information security industry. ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ovarian ... to think outside the bra. She doesn’t try to hide ... awareness about women’s other lady parts. , "We have won ... color pink and everybody knows what you’re talking about,” Jess-Huff ... has not been won when it comes to gynecologic cancers. ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2
... , FRIDAY, July 15 (HealthDay News) -- Injection ... treatment, regardless of what types of drugs they use, ... drug users suffer higher rates of abuse, dependence and ... could help treatment programs specialize their care to target ...
... Reporter , FRIDAY, July 15 (HealthDay News) -- New research ... that protects against hundreds of strains of meningococcus B ... Bacterial meningitis, an inflammation of the membranes covering the brain ... vaccines cover four of five types of bacteria that cause ...
... male baboons exhibit higher levels of stress hormones than ... a social hierarchy may be more costly than previously ... researchers, for the first time, identified higher levels of ... to beta males. "These results are very interesting ...
... Reinberg HealthDay Reporter , THURSDAY, July 14 (HealthDay News) ... that include smoking has dropped for the fifth year in a ... nearly 72 percent drop since 2005 in smoking images in movies ... smoking to 595 in 2010. In addition, the average number of ...
... , FRIDAY, July 15 (HealthDay News) -- In an ... number of governments have raised taxes on cigarettes, yet many ... new Canadian study. But the public health measure has ... the researchers recently reported in the International Journal of ...
... and Rome (July 15, 2011): The Lancet , a ... emphasizes the critical role of expanding access to HIV treatment ... pandemic. , The publication of the editorial comment coincides ... Pathogenesis, Treatment and Prevention (IAS 2011) taking place in Rome, ...
Cached Medicine News:Health News:Injection Drug Users Most in Need of Treatment, Study Says 2Health News:Researchers Closer to Developing Universal Meningitis B Vaccine 2Health News:Researchers Closer to Developing Universal Meningitis B Vaccine 3Health News:Less Lighting Up in Movies Aimed at Kids 2Health News:Less Lighting Up in Movies Aimed at Kids 3Health News:Cigarette Tax Unlikely to Deter Some Smokers: Report 2Health News:Roll out treatment as prevention now to stop HIV and AIDS 2
Used for drainage and retrograde pyelogram in pediatric patients. A stiffening stylet is included to aid in catheter placement. Supplied sterile in peel-open packages. Intended for one-time use....
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... internal drainage from the ureteropelvic ... sterile in peel-open packages. Intended ... evaluation is advised; polyurethane, C-Flex, ... remain indwelling more than six ...
... the urethra after hypospadias or epispadias ... of the bladder. The externalized portion ... length to allow drainage into a ... inside diaper dry during the healing ...
Medicine Products: